BRKB

480.35

-0.22%↓

BRKA.US

720,335.7

-0.21%↓

JPM

289.94

+1.14%↑

V

304.19

+0.85%↑

MA

500.63

+0.99%↑

BRKB

480.35

-0.22%↓

BRKA.US

720,335.7

-0.21%↓

JPM

289.94

+1.14%↑

V

304.19

+0.85%↑

MA

500.63

+0.99%↑

BRKB

480.35

-0.22%↓

BRKA.US

720,335.7

-0.21%↓

JPM

289.94

+1.14%↑

V

304.19

+0.85%↑

MA

500.63

+0.99%↑

BRKB

480.35

-0.22%↓

BRKA.US

720,335.7

-0.21%↓

JPM

289.94

+1.14%↑

V

304.19

+0.85%↑

MA

500.63

+0.99%↑

BRKB

480.35

-0.22%↓

BRKA.US

720,335.7

-0.21%↓

JPM

289.94

+1.14%↑

V

304.19

+0.85%↑

MA

500.63

+0.99%↑

Search

Main Street Capital Corp

Fermé

SecteurFinance

55.01 0.57

Résumé

Variation du prix de l'action

24h

Actuel

Min

54.02

Max

55.54

Chiffres clés

By Trading Economics

Revenu

-92M

32M

Ventes

19M

203M

P/E

Moyenne du Secteur

9.973

54.048

BPA

1.03

Rendement du dividende

5.5

Marge bénéficiaire

15.749

Employés

110

EBITDA

3.3M

137M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+24.17% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

5.50%

4.84%

Prochains Résultats

11 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-63M

5B

Ouverture précédente

54.44

Clôture précédente

55.01

Sentiment de l'Actualité

By Acuity

34%

66%

73 / 441 Classement par Finance

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Main Street Capital Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 mars 2026, 23:47 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mars 2026, 22:55 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mars 2026, 21:51 UTC

Acquisitions, Fusions, Rachats

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mars 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mars 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mars 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mars 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mars 2026, 22:42 UTC

Market Talk
Principaux Événements d'Actualité

Global Equities Roundup: Market Talk

23 mars 2026, 22:42 UTC

Market Talk
Principaux Événements d'Actualité

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mars 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mars 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mars 2026, 22:22 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mars 2026, 22:21 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mars 2026, 22:21 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mars 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mars 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mars 2026, 22:19 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mars 2026, 22:19 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mars 2026, 22:18 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mars 2026, 22:15 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mars 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mars 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mars 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mars 2026, 21:32 UTC

Résultats

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mars 2026, 21:32 UTC

Résultats

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mars 2026, 21:32 UTC

Résultats

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mars 2026, 21:10 UTC

Principaux Événements d'Actualité

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mars 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mars 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mars 2026, 20:50 UTC

Market Talk
Résultats
Principaux Événements d'Actualité

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

Main Street Capital Corp prévision

Objectif de Prix

By TipRanks

24.17% hausse

Prévisions sur 12 Mois

Moyen 68.33 USD  24.17%

Haut 74 USD

Bas 65 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

4 ratings

2

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

52.6034 / 54.64Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

73 / 441Classement par Finance

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Main Street Capital Corp

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations, and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies ranging between $5 million and $125 million in equity investment with annual revenues between $10 million and $150 million and EBITDA in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $150 million per transaction in debt investment value but holds the ability to lead debt financings up to $250 million and invests between $10 million and $150 million in credit solutions with EBITDA in the range of $5 million and $75 million for credit solutions. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minori
help-icon Live chat